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Late-onset diseases such as Alzheimer’s disease, Parkinson’s disease, or frontotemporal lobar degeneration are
considered to be protein-folding disorders, with the accumulation of protein deposits causing a gain-of-toxic
function. Alzheimer’s disease is characterized by two histological hallmark lesions: amyloid-β-containing plaques and
tau-containing neurofibrillary tangles. However, signature proteins, including α-synuclein, which are found in an
aggregated fibrillar form in the Lewy bodies of Parkinson’s disease brains, are also frequently found in Alzheimer’s
disease. This highlights the fact that, although specific aggregates form the basis for diagnosis, there is a high
prevalence of clinical overlap between neuropathological lesions linked to different diseases, a finding known as
cerebral co- or multi-morbidity. Furthermore, the proteins forming these lesions interact, and this interaction
accelerates an ongoing degenerative process. Here, we review the contribution that transgenic animal models have
made to a better mechanistic understanding of the causes and consequences of co- or multi-morbidity. We discuss
selected vertebrate and invertebrate models as well as the insight gained from non-transgenic senescence-accelerated
mouse-prone mice. This article is part of a series on ‘Cerebral multi-morbidity of the aging brain’.Introduction
A unifying feature of the pathology of neurodegenerative
diseases is the accumulation of misfolded proteins that
form insoluble aggregates in both the intra- and extra-
cellular space of the central nervous system. Tradition-
ally, the pathological classification of neurodegenerative
diseases has been based on the principal proteins that
are present in these aggregates and their localization to
distinct brain areas. However, it is rare for the deposited
proteins to be unique to one disease. In reality, although
specific aggregates form the basis for diagnosis, there is
a high prevalence of clinical overlap between neuro-
pathological lesions linked to different diseases, a finding
known as cerebral co- or multi-morbidity [1]. Clinical
and neuropathological findings are discussed in detail in
the articles that accompany our review as part of a series
on ‘Cerebral multi-morbidity of the aging brain’. Here,
we focus on the insight provided by animal models.
Of all the dementias, Alzheimer’s disease (AD) is the
most prevalent, accounting for approximately two thirds
of all cases. Neuropathologically, in addition to neuron* Correspondence: j.goetz@uq.edu.au
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sence of amyloid-β (Aβ)-containing plaques—with Aβ
being proteolytically derived from the larger amyloid pre-
cursor protein (APP)—as well as tau-containing neurofib-
rillary tangles (NFTs) and neuropil threads. It is, however,
becoming increasingly clear that these lesions often co-
exist with other forms of protein aggregates. In fact, about
two thirds of aged human AD brains contain additional
non-AD pathologies [2-6]. These include protein aggre-
gates of α-synuclein, a defining feature of Parkinson’s dis-
ease (PD) and dementia with Lewy bodies (DLB), as well
as transactive response DNA-binding protein 43 kDa
(TDP-43) that forms aggregates in subtypes of fronto-
temporal lobar degeneration (FTLD) and amyotrophic
lateral sclerosis (ALS), the latter also known as motor
neuron disease [7,8].
Age is the most important risk factor for AD. On the
one hand, the hypothesis has been formulated that AD
is an inevitable manifestation of senescence in that the
disease, with its neuropathological signatures, is consid-
ered a normal phenomenon of aging [9]. On the other
hand, the pattern of neuronal loss was shown to differ
between normal aging and AD, suggesting that the latter
is not an inevitable consequence of the former [10]. Inter-
estingly, however, a recent study indicates that much ofral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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neurodegenerative pathologies such as plaques and NFTs,
suggesting that other important determinants are still to
be identified [11].
In animals, age-related cognitive impairment or even
an AD-like pathology is seen in species that reach an ad-
vanced age. In fact, all non-human primate species ex-
amined to date have been shown to display NFTs, or Aβ
plaques, or both [12,13] (and references therein). Further
studies in these species are warranted. Plaques have been
reported in the brains of cetaceans (such as whales), birds,
fish, carnivorans (such as bears), and ungulates, and NFTs
have been reported in the latter two groups [14].
Modelling plaques and neurofibrillary tangles in
animals
Unfortunately, most of the above species are not easily
amenable to experimental manipulation, and the animal
species traditionally used in laboratory settings, such as
mice, flies, or worms, do not naturally develop the pro-
tein aggregates seen in AD, in part because of their rela-
tively short life span [14]. Nonetheless, these species
have been successfully developed into experimental ani-
mal models for AD by expressing pathogenic mutations
that are found in the genes encoding APP, presenilin-1,
and presenilin-2 in familial early-onset AD as well as
by expressing pathogenic mutations in the tau-encoding
MAPT (microtubule-associated protein tau) gene found
in familial cases of FTLD (FTDP-17t) [15].
It took several attempts for the research community
to succeed in reproducing the end-stage lesions of AD,
NFTs and plaques in transgenic mouse models [15]. The
discovery of pathogenic mutations, such as those in the
APP and MAPT genes, together with the use of stronger
promoters and inducible systems, made possible the re-
production of plaques and NFTs at reasonable numbers
and at a reasonable age. Overexpression of wild-type
forms of human tau did not reproduce NFTs [16-19] un-
less the mice reached a high age [20]. Similarly, crossing
wild-type human tau transgenic mice with mice carrying
the Osaka mutation in APP (E693Δ) resulted in NFT for-
mation at only 18 months of age [21]. However, expres-
sion of FTDP-17t mutant forms of tau resulted in a much
earlier onset of NFT formation [22,23], and by using an in-
ducible system for transgene expression, the initiation of
massive NFT formation has been achieved as early as
2.5 months of age [24].
Small-animal models such as the fruit fly Drosophila
melanogaster and the roundworm Caenorhabditis elegans
are useful tools for investigating human disorders, as the
genes implicated in human disease have homologues in
the invertebrates and because many signalling pathways
are conserved. For a review of the currently available
models of neurodegeneration in C. elegans, see [25]. Anadvantage of C. elegans lies in the fact that the biological
function of, for example, the tau homologue Ptl-1 can
be studied without the complication of functional re-
dundancy that is observed in mammals (where tau,
MAP2, and MAP4 have partly overlapping functions)
[26]. In Drosophila, the expression of human wild-type
and mutant forms of proteins with a role in AD, PD,
and FTLD has advanced our understanding of the role
of these proteins under physiological and pathological
conditions. Examples of such models are α-synuclein or
tau transgenic flies [27,28].
Interestingly, work in the roundworm C. elegans has
shown that the expression of both normal and FTDP-
17t mutant tau results in neurodegeneration and de-
fective neurotransmission but that the pathology is more
severe in the latter [29]. One of the key advantages of
the C. elegans system is the possibility of rapid and com-
parably cheap modifier screens; this has led, for example,
to the identification of sut-2 as being required for tau
neurotoxicity [30]. Earlier work in Drosophila had shown
that tau-dependent neurodegeneration can occur in the
absence of NFT formation [28] and that neuronal ex-
pression of wild-type tau in the absence of mutations
can cause learning and memory deficits [31]. Several
studies have addressed the individual roles of distinct
phosphorylation sites of tau, rather than hyperphosphor-
ylation per se, but more studies are required to pinpoint
the role of specific tau phosphorylation events and tau
isoforms in disease [32,33]. Importantly, highly phosphor-
ylated tau firstly exhibits significantly reduced binding to
microtubules and secondly participates in a pathogenic
interaction with normal tau, sequestering it away from
microtubules [34].
Studies in invertebrates and vertebrates have collect-
ively identified several modes of tau and Aβ dysfunction
and how this results in neurodegeneration [35,36]. Des-
pite the insight into pathomechanisms provided by these
models, transgenic approaches have met with criticism
because of (i) unphysiologically high protein levels that
are caused, for example, by the integration of multiple
transgene copies into the genome, (ii) an altered brain
area specificity and subcellular expression pattern of the
transgene compared with the endogenous gene because
of the use of an exogenous promoter, and (iii) disruption
or alteration of endogenous gene expression because of
insertion of the transgene into the host genome. Conse-
quently, several groups have pursued alternative strategies.
For example, more recently, a knock-in approach was
used to introduce the P301L mutation of tau into the
murine MAPT locus. Although these mice failed to de-
velop a mature tau pathology [37], this does not pre-
clude their use in dissecting early pathomechanisms,
and it is possible, with the advent of new gene-editing
methods, that these models can be further refined [38].
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senescence-accelerated SAMP (senescence-accelerated
mouse-prone) strain, that are characterized by accelerated
aging [39]. Together with a series of related senescence-
accelerated mice, the SAMP strains were established 40
years ago by conventional inbreeding of AKR/J-derived
mice that displayed features of accelerated aging such as
hair loss, reduced activity, shortened life expectancy, lor-
dokyphosis (increased curvature of the spine), and peri-
ophthalmic problems [40]. Littermates of mice that did
not show a senescence-associated phenotype were also
inbred to generate senescence-resistant, longer-lived
senescence-accelerated mouse resistant (SAMR) mice,
of which the SAMR1 strain is commercially available.
SAMP strains exhibit an early onset of age-related de-
cline in their immune system such as thymic involution,
loss of CD4+ T cells, impaired helper T-cell function,
decreased antibody-forming capacity, dysfunction of
antigen-presenting cells, decreased natural killer activ-
ity, increased auto-antibodies, and increased suscepti-
bility to viral infection [41].
SAMP8 is the strain that has been most extensively
analyzed in relation to cognitive functions [42]. These
mice are neuropathologically characterized by oxidative
changes similar to those found in the AD brain [43].
Furthermore, they have an impaired glucose metabolism
[44] and exhibit age-dependent reductions in various re-
ceptors, including the NMDA receptor [45]. Tau was
found to be pathologically phosphorylated in this strain,
but filament formation and NFT formation have not
been reported, indicating that the SAMP8 mice present
with an early tau pathology [46]. Staining with Aβ-specific
antibodies suggested Aβ deposition in these mice [47,48];
however, unlike the human sequence for the Aβ precursor
protein APP, the murine protein lacks the amino acids
that are required to generate Aβ, and as a result these
deposits have been termed ‘Aβ-like’ [47]. A more recent
study reported the presence of Aβ granules in the hippo-
campus, which contained also tau but not α-synuclein
[49]. Another study demonstrated elevated α-synuclein
levels in SAMP8 mice compared with senescence-resistant
SAMR1 mice, but aggregation of neither tau nor α-
synuclein was reported in these animals [50]. Together,
these findings limit the use of non-transgenic models
such as the SAMP mice to study multi-morbidity, in
part because authentic end-stage lesions do not form.
Comorbidity addressed in animal models
AD and PD are associated with the cerebral accumulation
of Aβ/tau and α-synuclein, respectively. Because many pa-
tients have clinical and pathological features of both dis-
eases, this raises several possibilities: (i) the pathogenetic
pathways overlap; (ii) the presence of one pathologically
altered protein (be it in its post-translational modifiedform or be it present as oligomer, fibril, or microscopically
visible aggregate) causes pathological changes to a protein
implicated in the other disease, which also includes the
formation of mixed aggregates; and finally (iii) synergistic
effects exist of Aβ and α-synuclein with regard to down-
stream toxicity (Figure 1).
Several in vitro studies have shown that these particu-
lar proteins cross-talk and cause each other’s aggrega-
tion. For example, Aβ and α-synuclein can form dimers
that dock on the plasma membrane and then incorpor-
ate additional α-synuclein molecules, leading to the for-
mation of more stable pentamers and hexamers that
adopt a ring-like structure, causing increased calcium
influx [51]. These interactions can result in oxidative
stress, lysosomal leakage, and mitochondrial dysfunction,
as has been discussed in detail by Crews and colleagues
[52]. These authors suggested that hybrid molecules of
Aβ and α-synuclein might embed not only in the plasma
membrane but also in membranes of mitochondria and
lysosomes, where they would form nanopore-like struc-
tures, which result in abnormal ion conductance. A re-
cent study with implications for DLB showed that the
metabotropic glutamate receptor mGluR5 has a role in
mediating Aβ oligomer toxicity in hippocampal neurons
and that the accumulation of α-synuclein fragments
makes these cells more vulnerable [53].
We will now discuss how α-synuclein interacts with
tau/Aβ in vivo and how this knowledge informs our un-
derstanding of comorbidity in AD. In 1993, α-synuclein
was identified as the non-Aβ component of AD amyloid
[54], and subsequently a plaque-associated α-synuclein
pathology was reported in aged amyloid-depositing mutant
APP transgenic Tg2576 mice [55]. Although there was
limited tau pathology, the mice displayed frequent neur-
ites that were both ubiquitin- and α-synuclein-positive.
When mutant APP transgenic mice were crossed with
α-synuclein overexpressing mice, α-synuclein oligomer
formation was significantly increased in the double-
transgenic animals [56]. The mice had severe deficits in
learning and memory, developed motor deficits earlier
than α-synuclein single-transgenic mice, and showed
prominent age-dependent degeneration of cholinergic
neurons and presynaptic terminals. They also had more
α-synuclein-immunoreactive neuronal inclusions than
observed in α-synuclein single-transgenic mice. In addi-
tion, some of these inclusions were fibrillar in nature,
whereas all inclusions in the single-transgenic mice were
amorphous. To address not only whether Aβ has an im-
pact on α-synuclein pathology but also whether the in-
verse could be true, the Tg2576 strain was crossed onto
an α-synuclein knockout background. This resulted in
an increased amyloid plaque load, leading the authors
to speculate that α-synuclein is not involved in the
seeding of the plaques but rather that it suppresses the
Figure 1 Potential modes of comorbidity. In neurodegenerative disorders there are protein insults considered imperative to the development
and characterization of a specific disease (hallmark lesion A) and additional protein pathology that is traditionally classified to another disease
state (hallmark lesion B). There are several potential mechanisms by which cross-talk may be occurring between these separate lesions to result in
comorbidity: i) at the level of the initial pathogenic signalling cascades which results in the formation of seeds A and B, respectively, (ii) through
the ability of one pathological protein (which could range from a post-translational modification state through to a mature aggregate) to induce
pathological changes in the state of a protein implicated in another disease, which may also lead to the formation of mixed aggregates, and
(iii) a convergence onto mutual cell death pathways.
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the disease [57].
The impact that α-synuclein expression has on tau
has also been addressed in transgenic mouse models.
Giasson and colleagues [58] showed that co-incubation
of tau and α-synuclein promotes the fibrillization of
both proteins. Using negative contrast electron micros-
copy, they further demonstrated the presence of bun-
dled filaments that were labelled with antibodies for
both proteins. They also investigated the formation of tau
inclusions in A53T mutant α-synuclein transgenic miceand found that, compared with single-transgenic mice,
aggregate formation in α-synuclein/P301L tau bigenic
mice was accelerated by 6 months. Increased hyperpho-
sphorylation of tau was observed in several additional
α-synuclein transgenic mouse models [59-61], and a study
in E46K mutant α-synuclein transgenic mice revealed that
two pathological phospho-epitopes of tau, AT100 and
PHF1 (which is a target of several tau immunization stud-
ies), were induced by α-synuclein [61]. The abundance of
tau inclusions in the E46K transgenic mice was greater
than observed previously in A53T human α-synuclein
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in α-synuclein-mediated tau hyperphosphorylation is
glycogen synthase kinase 3β (GSK-3β), one of the major
tau kinases. It was shown by co-immunoprecipitation that
α-synuclein, GSK-3β, and tau phosphorylated at the
PHF1 epitope pSer396/404 exist as a heterotrimeric com-
plex in human SH-SY5Y neuroblastoma cells [62]. The
crosstalk of α-synuclein and tau was further addressed in
Drosophila, where misexpression of wild-type α-synuclein
was found to enhance a tau-mediated rough eye pheno-
type and apoptotic cell death in the eye. Similarly, α-
synuclein increased tau-dependent abnormal microtubule
organization and axonal transport impairment, together
with an enhanced tau-induced motor phenotype [63]. In-
terestingly, the study also found that co-expression of
α-synuclein and tau led to decreases in synapsin (a synap-
tic vesicle-associated phosphoprotein) in synaptic bou-
tons, resulting in synaptic apposition defects consistent
with synaptic retraction.
Another study addressed the mechanism by which
human tau (a strong risk factor for PD) predisposes an
individual to PD [64]. This study found that expression
of human wild-type tau was sufficient to disrupt the
survival of dopaminergic neurons in a Drosophila model
and to cause a progressive impairment of motor and
learning behaviours. Interestingly, it also demonstrated
that, contrary to the common notion that hyperpho-
sphorylated tau aggravates toxicity, the degeneration of
dopaminergic neurons was alleviated by expressing a
pseudo-hyperphosphorylated form of tau, E14. Several
studies used Drosophila to better understand the role of
APP/Aβ in neurodegeneration [65,66] and more specific-
ally to demonstrate that Aβ exacerbates tau pathology [67].
After the finding that Aβ toxicity in AD can be dra-
matically reduced by removing tau [68,69], whether this
holds true for α-synuclein was also addressed. However,
in two PD models—one pharmacological (by striatal in-
jection of 6-hydroxydopamine) and the other a human
wild-type α-synuclein transgenic strain—tau reduction
did not prevent the motor deficits that characterize these
models [70].
To determine how the three key players in AD/PD—
Aβ, tau, and α-synuclein—interact, the A53T mutant
α-synuclein transgene was introduced into 3xTg-AD mice,
a strain characterized by both plaque and NFT pathology
[71]. As in human disease, the mice developed both DLB
and AD pathologies. Lewy body-like pathology was in-
creased upon co-expression of APP and tau. Tau solubility
was decreased and its phosphorylation increased in the
crossbred mice, as were levels of detergent-insoluble Aβ
(observed for both the Aβ40 and Aβ42 species). Moreover
co-expression of the three proteins accelerated the cogni-
tive decline, with evidence that α-synuclein exacerbated
cognitive deficits not only in the acquisition of spatialrecognition memory but also in the retention of memory.
It was further found that accumulation of α-synuclein
alone could significantly disrupt cognition. A different re-
sult was reported in a crossbreed of three strains, A53T α-
synuclein mutant mice, Tg2576 and a P264L presenilin-1
knock-in strain that further promotes Aβ plaque forma-
tion. Here, despite the accumulation of dystrophic neurites
that were positive for hyperphosphorylated α-synuclein
both within and surrounding Aβ plaques, no additional α-
synuclein pathologies were observed. It was concluded that
Aβ deposits can cause the local aggregation of α-synuclein
but that this does not lead to a more extensive α-synuclein
pathology [72].
Considering evidence that soluble, non-fibrillar Aβ
(and tau) may be the more neurotoxic species, Larson
and colleagues [73] assessed the putative role of soluble
α-synuclein in AD. They first showed that there is an
approximately twofold increase in monomeric, intracel-
lular α-synuclein in brains from AD patients compared
with normal controls and subjects suffering from mild
cognitive impairment. This accumulation was found to
be independent of Lewy body formation. Interestingly,
mRNA levels were also increased approximately two-
fold in AD patients compared with controls, suggesting
the involvement of imbalanced synuclein gene expression.
The level of soluble α-synuclein was linked to AD-
associated cognitive impairment and was also a good
predictor of AD-related impairment. When transgenic
mice were analyzed, neither of the two APP mutant lines,
Tg2576 and J20, aged between 1 and 17 months, pre-
sented with detectable changes in soluble α-synuclein. To
test whether expression of human tau is required for the
regulation of α-synuclein expression, soluble α-synuclein
protein levels were compared in Tg2576 mice, P301L tau
over-expressing rTg4510 mice, and Tg2576 × rTg4510
mice. This revealed an approximately twofold increase in
soluble α-synuclein at 8 months in Tg2576 × rTg4510
mice, whereas no obvious changes were found in rTg4510
mice across all age groups. These findings indicate that a
synergism between Aβ/APP and human tau is required to
upregulate α-synuclein expression levels.
An exciting study published in 2013 revealed distinct
α-synuclein strains that differentially promote tau in-
clusions in neurons [74]. Based on the use of exogenous
pre-formed fibrils (termed ‘pffs’) of α-synuclein, two
strains (A and B) were generated with a differential abi-
lity to cross-seed tau aggregation in cultured neurons.
Furthermore, stereotaxic injections of the hippocampus
of P301S mutant tau transgenic PS19 mice revealed that
differential cross-seeding occurs in vivo. At 3 months
post-injection, only rare cells showed abnormal accu-
mulation of hyperphosphorylated tau, recognized by the
AT8 antibody near the injection site of strain A-inoculated
mice, whereas numerous neurons bearing AT8-positive
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around the same area. Moreover, strain B-injected mice
not only displayed significantly more tau inclusions
throughout the hippocampus, including regions that
were more rostral and caudal to the injection site, but
also consistently showed phospho-tau aggregates in
the contralateral hippocampus and even the locus
coeruleus, a brainstem structure distant from the injec-
tion site, indicating the presence of transmission of tau
pathology cross-seeded by α-synuclein pffs. The differ-
ential induction of tau aggregates was further con-
firmed with a set of antibodies to detect pathological
conformations of tau [74].
To date, only a few studies have addressed the effect
that other proteins implicated in neurodegeneration
have on Aβ, tau, and α-synuclein. Cross-rescue experi-
ments and co-expression models using TDP-43 and FUS
(fused in sarcoma) transgenic flies have provided evi-
dence for a genetic interaction of the two proteins in a
common pathway, suggesting a convergence of molecu-
lar pathways influencing FTLD (and ALS) pathology
[75,76]. It has also been shown that inoculation of the
brains of α-synuclein transgenic mice with prions (PrPSc)
exacerbates the α-synuclein pathology. Remarkably, prion
pathology was unmodified by the presence of α-synuclein
[77]. Of the proteins other than tau that form aggregates
in FTLD, TDP-43, and FUS, only TDP-43 has been ana-
lyzed in transgenic mouse models of tauopathy [78]. Cyto-
plasmic accumulation of phosphorylated TDP-43 was
specifically found in two tau transgenic models (P301L
0N4R-expressing rTg4510 mice and JNPL3 mice), but
TDP-43 pathology was absent in mouse models of Aβ de-
position (TgCRND8, Tg2576, and Tg2576 x P264L PS1
knock-in), α-synucleinopathy (A53T-expressing M83 mice
and E46K-expressing M47 mice), or Huntington’s disease
(N586-82Q-C63 model). These data demonstrate that
the neurodegenerative cascade associated with a pri-
mary tauopathy in tau transgenic mice can also promote
TDP-43 abnormalities.Conclusions
What are possible explanations for co- or multi-morbidity
and what have animal models contributed to a better
understanding of this? As it stands, late-onset diseases
are mainly protein-folding diseases, with the accumula-
tion of protein deposits causing a gain-of-function pro-
teotoxicity [79]. The concept that has been put forward
is that the proteostasis machinery is overwhelmed when
there is a chronic elevation of misfolded proteins. Mo-
lecular chaperones and other components of the ‘clear-
ance machinery’ become trapped in the aggregates and
this compromises the re-folding of other aggregation-
prone proteins and facilitates their aggregation [79].Alternatively, filamentous aggregates that are composed
of one protein may directly cross-seed other amyloido-
genic proteins because of potentially shared structural
features of amyloid fibrils [80]. As has been argued for
the interaction of α-synuclein and tau, α-synuclein might
alter the conformation or solubility of tau in brains
with tau inclusions, even in the absence of an obvious
α-synuclein pathology. As only minute amounts of amy-
loidogenic α-synuclein seeds may be required, it is pos-
sible that they are undetectable with current methods
or, alternatively, are degraded after they initiate tau
polymerization [80]. There is strong support for both
hypotheses from in vitro experiments as well as the
in vivo studies discussed here.
To address whether amyloid deposition associated with
AD perturbs the proteostasis network, APPswe/PS1dE9
transgenic mice with a high amyloid burden were investi-
gated in order to determine whether cytosolic brain pro-
teins would lose their solubility. Using a method that
involved detergent extraction and sedimentation coupled
with proteomic approaches, this study identified numer-
ous cytosolic proteins that show specific losses in solu-
bility as amyloid accumulates. The identified proteins
included glycolytic enzymes as well as members of the
14-3-3 chaperone family. A substantial accumulation of
lysine 48-linked polyubiquitin was also detected [81].
Furthermore, a recent study in C. elegans has shown
that widespread protein aggregation is an inherent part
of aging in worms [82], and by extension this could be
assumed to hold true for humans.
The identification of cross-seeding raises the question
of whether the neurodegeneration pathways are unique
to different diseases or not. Transgenic Drosophila ex-
pressing human α-synuclein faithfully replicate essential
features of human PD, including age-dependent loss of
dopaminergic neurons, Lewy-body-like inclusions, and
locomotor impairment. To define the transcriptional
program involved in α-synuclein pathology, the expres-
sion of the entire Drosophila genome at pre-symptomatic,
early, and advanced disease stages was determined. Fifty-
one signature transcripts were tightly associated with
α-synuclein expression, whereas in age-matched tau
transgenic Drosophila, the transcription of α-synuclein-
associated genes was normal, suggesting highly distinct
pathways of neurodegeneration [83]. However, once the
aggregates have formed, they have been shown to de-
regulate similar pathways and protein categories. This
is the case even for proteins that aggregate in different
organs. In support of this, Aβ and the amyloidogenic
protein amylin, which forms aggregates in the pancreas
of patients with type 2 diabetes, deregulate the same
functional categories in cell culture systems; in fact,
these two toxic molecules even show a great overlap in
deregulated proteins [84].
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and the analysis of human brain tissue support in vitro
studies revealing comorbidity in neurodegenerative dis-
ease. These studies highlight the involvement of both
cross-seeding of the aggregating proteins, synergistic ef-
fects in their toxicity, and a vicious cycle of compro-
mised aggregate clearance and protein aggregation.Note: This article is part of a series on Cerebral multi-morbidity
of the aging brain edited by Johannes Attems and Julie
Schneider. Other articles in the series can be found at http://
alzres.com/series/cerebral_multimorbidity.Abbreviations
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